Uptool | $6,000,000 | (Feb 10, 2026)
microsynetics GmbH | $10,000,000 | (Feb 10, 2026)
Linkup(US) | $10,000,000 | (Feb 10, 2026)
Certified by Founder
Lodge
Ratio Therapeutics
start up
United States
- Boston, MA
- 02/12/2021
- Unknown
- $1,500,000
A discovery through early clinical phase pharmaceutical company, Ratio Therapeutics employs a suite of innovative technologies to develop best-in-class targeted radiotherapeutics for the treatment of cancer.
Ratio Therapeutics’ Trillium™ targeting scaffold combines pharmacokinetic modulation with best-in-class chelation technology to create proprietary small molecule targeting agents to attack a broad array of cancer targets. Our compounds accommodate imaging and therapeutic radioisotopes, ie "theranostics". The tunable nature of our platform combined with small-scale imaging trials in patients results in accelerated, de-risked compound selection.
- Industry Pharmaceutical Manufacturing
- Website https://ratiotx.com/
- LinkedIn https://www.linkedin.com/company/rat
Phylo | $13,500,000 | (Feb 10, 2026)
pHathom Technologies, Inc | $4,000,000 | (Feb 10, 2026)
Qontext | $2,700,000 | (Feb 10, 2026)
Bound | $24,500,000 | (Feb 10, 2026)
Sentra(US) | $5,000,000 | (Feb 10, 2026)
adaption | $50,000,000 | (Feb 6, 2026)
Nixtla | $16,000,000 | (Feb 6, 2026)
Advance | $8,550,000 | (Feb 6, 2026)
Uplift360 | $8,724,008 | (Feb 6, 2026)